Abstract
![Figure][1]</img> Dear ISHRS Members, The following information comes from my research while trying to understand the possible impact of the May 31, 2021, date that marked the end of the U.S. Food & Drug Administration’s (FDA’s) grace period for certain regenerative medicine products.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
